Zoetis (ZTS)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$75.81-0.63%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
Research Workspace
Put ZTS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Sustain revenue growth near guidance level: FY26 revenue guidance $9.12B-$9.32B vs $9.82B target.
View ThesisRevenue growth is slowing — up about 1% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 8%.
View QualityManagement screens strong on capital allocation, earnings delivery.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 53% in its worst 12-month stretch.
View RiskZoetis must sustain revenue growth near guidance levels to justify its current price. The latest earnings beat showed a strong performance, with revenue guidance set at $9.12B-$9.32B. It trades at 11.5× P/E, below the 16.1× peer median, indicating expectations look modest versus our view. The primary risk is a potential guidance cut, which could negatively impact future estimates. Peer multiples imply a price about 3% below where it trades. This read is provisional.
Trailing returns as of 2026-09-04. ZTS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering ZTS (as of Sep 2026).
Based on 6 Wall Street analysts offering 12-month price targets for ZTS in the last 4 months.
Continue this research
Compare ZTS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ZTS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Compare the value case
Put ZTS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive revenue growth with new product approvals
New product approval supports revenue growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $75.81
The last 12 months of price, then the range of analyst 12-month targets from today’s $75.81.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Revenue growth guidance for 2026
Stock price target cut indicates revenue growth concerns.
Threatens: Revenue growth guidance for 2026
Concerns about growth story impact future guidance.
Leadership changes may impact strategic execution and guidance.
Threatens: Revenue growth guidance for 2026
2026 revenue forecast cut amid pressures.
Threatens: Revenue growth guidance for 2026
Guidance cut reflects weakening growth outlook.
Threatens: Revenue growth guidance for 2026
Mixed results and guidance cut raise concerns.
Threatens: Drive revenue growth with new product approvals
Drug competition pressures revenue growth.
